April 17 (Reuters) - The U.S. Food and Drug Administration has approved Gamida Cell Ltd's blood cancer therapy, Omisirge, the health regulator said on Monday. (Reporting by Pratik Jain in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 USD | +2.41% | -.--% | -95.88% |
06-18 | Gamida Cell Names Rory Nealon as Chief Financial Officer | CI |
06-18 | Gamida Cell Names Sheila Frame as Chief Commercial Officer | CI |
1st Jan change | Capi. | |
---|---|---|
-95.88% | 2.62M | |
+15.85% | 121B | |
+18.91% | 112B | |
+4.43% | 22.57B | |
-18.63% | 20.82B | |
-13.76% | 16.3B | |
-16.61% | 16.19B | |
-43.53% | 16.17B | |
+1.75% | 13.17B | |
+28.07% | 11.11B |
- Stock Market
- Equities
- GMDA Stock
- News Gamida Cell Ltd.
- US FDA approves Gamida's blood cancer therapy